SC
KYNB

Sculptor Capital’s Kyntra Bio KYNB Stock Holding History

Sculptor Capital’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-52,747
Closed -$41.4M – 427
2015
Q1 		$41.4M Hold
52,747
– – 0.13% 119
2014
Q4 		$36.1M Buy
+52,747
New +$33.9M 0.1% 179

Other funds holding KYNB

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Sculptor Capital's KYNB Position: Q2 2015 in Review

Sculptor Capital sold out of Kyntra Bio (KYNB) in Q2 2015, closing a stake of 52,747 shares — an estimated $41.4M sold.

Sculptor Capital first reported a position in KYNB in Q4 2014 and held it in 2 quarters. The position peaked at $41.4M in Q1 2015. 96 funds tracked by Wall St. Rank hold KYNB as of Q2 2015.

  • Sculptor Capital reported no remaining Kyntra Bio position as of Q2 2015 after selling out during the quarter.
  • Sculptor Capital sold 52,747 Kyntra Bio shares in Q2 2015, an estimated $41.4M.
  • Sculptor Capital first reported a position in Kyntra Bio in Q4 2014 and held it in 2 quarters.
  • Sculptor Capital's Kyntra Bio position peaked at $41.4M in Q1 2015.
  • 96 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2015.

Based on Sculptor Capital's 13F filing for Q2 2015, filed 14 Aug 2015.